Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.67 |
| ▸ | MGLL | Q99685 | 13/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.57 |
| ▸ | HTR3B | O95264 | 1/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13363263 | 0.86 | HTR3A (0.76) | HTR3AMGLL | |
| SCHEMBL29520225 | 0.85 | HTR3A (0.74) | HTR3AMGLL | |
| SCHEMBL20897573 | 0.84 | HTR3A (0.72) | HTR3AMGLL | |
| SCHEMBL20898065 | 0.83 | MGLL (0.72) | HTR3AMGLL | |
| Hydrochloric Acid SCHEMBL20897547 | 0.82 | HTR3A (0.70) | HTR3AMGLL | |
| Hydrochloric Acid SCHEMBL20897549 | 0.82 | HTR3A (0.70) | HTR3AMGLL | |
| SCHEMBL2420509 | 0.82 | HTR3A (0.70) | HTR3AMGLLMAPT | |
| Hydrochloric Acid SCHEMBL29784162 | 0.82 | HTR3A (0.70) | HTR3AMGLL | |
| SCHEMBL5321169 | 0.81 | HTR3A (0.67) | HTR3AMGLLMAPTALDH1A1TSHR | |
| Acetic Acid SCHEMBL20897485 | 0.81 | HTR3A (0.67) | HTR3AMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099622-A1 | COMPOSITIONS AND METHODS FOR EXPRESSING THERAPEUTICS | Avirmax Biopharma Inc. | 2025-03-27 | — | — | US | disclosed |
| US-20240092866-A1 | COMPOSITIONS AND METHODS FOR OCULAR TRANSGENE EXPRESSION | Avirmax Biopharma Inc. | 2024-03-21 | — | — | US | disclosed |
| US-20240035045-A1 | ENGINEERED VIRAL CAPSIDS AND METHODS OF USE | Avirmax Biopharma Inc. | 2024-02-01 | — | — | US | disclosed |